Press reviews
2025-11-20
Prostatectomy or SBRT: which treatment better preserves quality of life?
Urology-nephrology Oncology
By Lila Rouland | Published on November 20, 2025 | 3 min read
In men with localized prostate cancer at low or intermediate risk, two curative treatments are now standard options: radical prostatectomy and stereotactic body radiotherapy (SBRT). While surgery is often regarded as the more radical approach, radiotherapy is considered less invasive, but its side effects—particularly bo...
In men with localized prostate cancer at low or intermediate risk, two curative treatments are now standard options: radical prostatectomy and stereotactic body radiotherapy (SBRT). While surgery is often regarded as the more radical approach, radiotherapy is considered less invasive, but its side effects—particularly bo...
Read more
By Carolina Lima | Published on November 20, 2025 | 3 min read
The digital rectal exam (DRE) has historically been a key tool in the early detection of prostate cancer (PCa). Before the widespread use of prostate-specific antigen (PSA) testing, DRE was the primary method for identifying potentially aggressive tumors. PSA transformed early detection by identifying cancers even in asy...
The digital rectal exam (DRE) has historically been a key tool in the early detection of prostate cancer (PCa). Before the widespread use of prostate-specific antigen (PSA) testing, DRE was the primary method for identifying potentially aggressive tumors. PSA transformed early detection by identifying cancers even in asy...
Read more
2025-11-19
Oncology
By Lila Rouland | Published on November 19, 2025 | 3 min read
Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage of the disease, commonly treated with androgen deprivation therapy (ADT). Although this strategy improves survival, it often leads to a deterioration in quality of life (QoL), with side effects such as fatigue, cognitive impairment, bone...
Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage of the disease, commonly treated with androgen deprivation therapy (ADT). Although this strategy improves survival, it often leads to a deterioration in quality of life (QoL), with side effects such as fatigue, cognitive impairment, bone...
Read more
2025-11-18
Oncology
By Lila Rouland | Published on November 18, 2025 | 3 min read
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing g...
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing g...
Read more
2025-11-17
Treatment of prostate cancer with GnRH agonists: what is the real impact on quality of life?
Urology-nephrology Oncology
By Lila Rouland | Published on November 17, 2025 | 3 min read
Prostate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL...
Prostate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL...
Read more
By Lila Rouland | Published on November 14, 2025 | 2 min read
The emergence of immunotherapies, particularly immune checkpoint inhibitors (ICIs), has revolutionized the management of many cancers. However, only a minority of patients derive durable benefit. Current biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have significa...
The emergence of immunotherapies, particularly immune checkpoint inhibitors (ICIs), has revolutionized the management of many cancers. However, only a minority of patients derive durable benefit. Current biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have significa...
Read more
2025-11-13
Oncology
By Lila Rouland | Published on November 13, 2025 | 4 min read
Metastatic castration-sensitive prostate cancer (mCSPC) remains a major public health challenge for men worldwide. Historically, its management relied on androgen deprivation therapy (ADT) alone. However, advances in understanding the androgen receptor (AR) signaling pathway have profoundly changed therapeutic strategies...
Metastatic castration-sensitive prostate cancer (mCSPC) remains a major public health challenge for men worldwide. Historically, its management relied on androgen deprivation therapy (ADT) alone. However, advances in understanding the androgen receptor (AR) signaling pathway have profoundly changed therapeutic strategies...
Read more
2025-11-12
Darolutamide: Will it redefine the initial treatment strategy in metastatic prostate cancer?
Oncology
By Lila Rouland | Published on November 12, 2025 | 3 min read
For many years, metastatic castration-sensitive prostate cancer (mCSPC) was treated exclusively with androgen deprivation therapy (ADT). However, recent therapeutic advances have led to the emergence of combination strategies, particularly those involving androgen receptor signaling inhibitors (ARSi). Among these agents,...
For many years, metastatic castration-sensitive prostate cancer (mCSPC) was treated exclusively with androgen deprivation therapy (ADT). However, recent therapeutic advances have led to the emergence of combination strategies, particularly those involving androgen receptor signaling inhibitors (ARSi). Among these agents,...
Read more
2025-11-12
Darolutamide, undetectable PSA, and prolonged survival: a new standard in prostate cancer treatment?
Oncology
By Lila Rouland | Published on November 12, 2025 | 3 min read
Metastatic hormone-sensitive prostate cancer (mHSPC) is undergoing a therapeutic revolution with the introduction of intensified combination regimens incorporating darolutamide.
The ARASENS study, which demonstrated a survival benefit with the addition of darolutamide to androgen deprivation therapy (ADT) and doc...
Metastatic hormone-sensitive prostate cancer (mHSPC) is undergoing a therapeutic revolution with the introduction of intensified combination regimens incorporating darolutamide.
The ARASENS study, which demonstrated a survival benefit with the addition of darolutamide to androgen deprivation therapy (ADT) and doc...
Read more
2025-11-10
Oncology
By Lila Rouland | Published on November 10, 2025 | 3 min read
Metastatic hormone-sensitive prostate cancer (mHSPC) is a clinical entity in which combination therapies have significantly improved overall survival. However, despite these advances, interindividual variability in treatment response remains high, making it difficult to identify patients at high risk of progression.
Metastatic hormone-sensitive prostate cancer (mHSPC) is a clinical entity in which combination therapies have significantly improved overall survival. However, despite these advances, interindividual variability in treatment response remains high, making it difficult to identify patients at high risk of progression.
Read more
By Lila Rouland | Published on November 10, 2025 | 4 min read
Metastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occu...
Metastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occu...
Read more
By Lila Rouland | Published on November 7, 2025 | 3 min read
A recent study published in Nature has revealed a surprising and hopeful connection between COVID-19 mRNA vaccines and improved survival outcomes in patients with certain types of cancer. The research, which focused on individuals undergoing immunotherapy for melanoma and non-small-cell lung cancer, found that those who re...
A recent study published in Nature has revealed a surprising and hopeful connection between COVID-19 mRNA vaccines and improved survival outcomes in patients with certain types of cancer. The research, which focused on individuals undergoing immunotherapy for melanoma and non-small-cell lung cancer, found that those who re...
Read more
By Lila Rouland | Published on November 6, 2025 | 3 min read
Localized (non-metastatic) prostate cancer affects a large male population and generally carries a good prognosis. However, patients remain at elevated risk of all-cause mortality, often due to comorbidities such as cardiovascular disease.
Diet is known to influence the course of many chronic illnesses, but its...
Localized (non-metastatic) prostate cancer affects a large male population and generally carries a good prognosis. However, patients remain at elevated risk of all-cause mortality, often due to comorbidities such as cardiovascular disease.
Diet is known to influence the course of many chronic illnesses, but its...
Read more
By Lila Rouland | Published on November 6, 2025 | 3 min read
Prostate cancer is the second most common cancer in men worldwide. Its incidence varies greatly depending on geography, ethnicity, and, most importantly, lifestyle factors, particularly diet. This review explores how fats, proteins, carbohydrates, vitamins, and phytonutrients influence the development and progre...
Prostate cancer is the second most common cancer in men worldwide. Its incidence varies greatly depending on geography, ethnicity, and, most importantly, lifestyle factors, particularly diet. This review explores how fats, proteins, carbohydrates, vitamins, and phytonutrients influence the development and progre...
Read more
2025-11-05
Do vitamins protect against or promote prostate cancer? a matter of source and dosage
Oncology
By Lila Rouland | Published on November 5, 2025 | 3 min read
Prostate cancer (PCa) is the fifth leading cause of cancer-related death among men worldwide. While traditional risk factors (age, ethnicity, metabolic syndrome) are well established, the role of vitamins in prostate cancer prevention remains controversial. Some studies suggest a protective effect, while others indicate a...
Prostate cancer (PCa) is the fifth leading cause of cancer-related death among men worldwide. While traditional risk factors (age, ethnicity, metabolic syndrome) are well established, the role of vitamins in prostate cancer prevention remains controversial. Some studies suggest a protective effect, while others indicate a...
Read more
